{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ballav C"],"funding":["National Institute for Health Research (NIHR)","NNF Center for Basic Metabolic Research","University of Oxford"],"pagination":["e00130"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375047"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(3)"],"pubmed_abstract":["<h4>Aims</h4>The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).<h4>Methods</h4>In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).<h4>Results</h4>PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, <i>P</i> = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, <"],"journal":["Endocrinology, diabetes & metabolism"],"pubmed_title":["Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients."],"pmcid":["PMC7375047"],"funding_grant_id":["NF-SI-0515-10096","Holst Group"],"pubmed_authors":["Dhere A","Agbaje OF","Ballav C","Franklin R","Holst JJ","Holman RR","White S","Hartmann B","Owen KR","Kennedy I"],"additional_accession":[]},"is_claimable":false,"name":"Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post-meal glucose excursions and glucagon in type 1 diabetes patients.","description":"<h4>Aims</h4>The GLP1 agonist lixisenatide is glucagonostatic and reduces post-prandial blood glucose (PPBG) in type 2 diabetes. This study investigates its impact in type 1 diabetes (T1D).<h4>Methods</h4>In a blinded, crossover trial, 25 patients with T1D were randomised to 4 weeks adjunctive treatment with lixisenatide (L) or placebo (P), with a 4-week washout period. The primary outcome was percentage of 3 hours PPBG in target (4-10 mmol/L) assessed by CGM before and after treatment. Participants also underwent post-treatment standardised mixed meal test (MMT, n = 25) and hyperinsulinaemic hypoglycaemic clamp (n = 15).<h4>Results</h4>PPBG CGM readings in target were similar between L vs P (Mean % ± SE, breakfast 45.4 ± 6.0 vs 44.3 ± 6.0, <i>P</i> = .48, lunch 45.5 ± 5.8 vs 50.6 ± 5.3, <","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-19T11:39:18.772Z","creation":"2025-04-19T11:39:18.772Z"},"accession":"S-EPMC7375047","cross_references":{"pubmed":["32704555"],"doi":["10.1002/edm2.130"]}}